New therapeutic strategies in the second line setting of advanced or metastatic pancreatic adenocarcinoma: Highlights from the "2013 ASCO Annual Meeting". Chicago, IL, USA; May 30 - June 4, 2013

Journal of the Pancreas

Volumn 14, Issue 4, 2013, Pages 344-346

  Ramfidis, Vasilis Stefanos ^a   Syrigos, Kostas N ^b   Wasif Saif, Muhammad ^c  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

Antineoplastic agents; Drug therapy; Pancreatic neoplasms

Indexed keywords

CAPECITABINE; DOCETAXEL; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; PACLITAXEL; SELUMETINIB;

ADVANCED CANCER; AMERICAN SOCIETY OF CLINICAL ONCOLOGY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; HEALTH CARE PLANNING; HUMAN; MEDICAL EDUCATION; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ADENOCARCINOMA; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; HUMANS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PANCREATIC NEOPLASMS; QUINAZOLINES; TAXOIDS; TREATMENT OUTCOME;

EID: 84880058033     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
2. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676-81. doi: 10.1016/j.ejca.2011.04.011. Epub 2011 May 10.
3. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15;113(8):2046-52. doi: 10.1002/cncr.23810.
4. Maisey N, Chau I, Cunningham D, et al. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002;20:3130-3136
5. Ettrich T, Goetz von Wichert, Gress T, Michl P, Geissler M, Hebart H, et al. DOCOX: A phase II trial with docetaxel and oxaliplatin as a second-line systemic therapy for patients with advanced and/or metastatic adenocarcinoma of the pancreas. J Clin Oncol 31, 2013 (suppl; abstr 4034)
6. Ko A, Tempero M, Bekaii-Saab T, Kuhn P, Courtin R, Ziyeh S, et al. Dual MEK/EGFR inhibition for advanced, chemotherapyrefractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib. J Clin Oncol 31, 2013 (suppl; abstr 4014)
7. Diep CH, Munoz RM, Choudhary A, Von Hoff DD, Han H. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res. 2011 May 1;17(9):2744-56.
8. Vaccaro V, Bria E, Reni M, Sperduti I, Gelibter A, Nuzzo C, et al. Activity of nab-paclitaxel (nab-P) monotherapy in heavily pretreated pancreatic cancer (aPDAC) patients (pts): A multicenter retrospective analysis. J Clin Oncol 31, 2013 (suppl; abstr e15057)